Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP262872.RAkQBhc-BcM4Mf9-cKqXFDtqRXlqCQB_tEfoZ8X5eqH3M130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP262872.RAkQBhc-BcM4Mf9-cKqXFDtqRXlqCQB_tEfoZ8X5eqH3M130_assertion type Assertion NP262872.RAkQBhc-BcM4Mf9-cKqXFDtqRXlqCQB_tEfoZ8X5eqH3M130_head.
- NP262872.RAkQBhc-BcM4Mf9-cKqXFDtqRXlqCQB_tEfoZ8X5eqH3M130_assertion description "[However, in oncogene-positive cases (BRAF(V600E) and RET/PTC1), tumors with CNA/UPD were less frequent (5/15, 33%), whereas tumors with CNA/UPD were more frequent in oncogene-negative cases (7/10, 70%), suggesting that chromosomal aberrations may play a role in the development of PTC, especially in oncogene-negative tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP262872.RAkQBhc-BcM4Mf9-cKqXFDtqRXlqCQB_tEfoZ8X5eqH3M130_provenance.
- NP262872.RAkQBhc-BcM4Mf9-cKqXFDtqRXlqCQB_tEfoZ8X5eqH3M130_assertion evidence source_evidence_literature NP262872.RAkQBhc-BcM4Mf9-cKqXFDtqRXlqCQB_tEfoZ8X5eqH3M130_provenance.
- NP262872.RAkQBhc-BcM4Mf9-cKqXFDtqRXlqCQB_tEfoZ8X5eqH3M130_assertion SIO_000772 22558328 NP262872.RAkQBhc-BcM4Mf9-cKqXFDtqRXlqCQB_tEfoZ8X5eqH3M130_provenance.
- NP262872.RAkQBhc-BcM4Mf9-cKqXFDtqRXlqCQB_tEfoZ8X5eqH3M130_assertion wasDerivedFrom befree-20140225 NP262872.RAkQBhc-BcM4Mf9-cKqXFDtqRXlqCQB_tEfoZ8X5eqH3M130_provenance.
- NP262872.RAkQBhc-BcM4Mf9-cKqXFDtqRXlqCQB_tEfoZ8X5eqH3M130_assertion wasGeneratedBy ECO_0000203 NP262872.RAkQBhc-BcM4Mf9-cKqXFDtqRXlqCQB_tEfoZ8X5eqH3M130_provenance.